This morning, Forest Labs (FRX) announced it had agreed to acquire Aptalis for $2.9 billion in cash. Aptalis is a privately held company that specializes in treatments for both cystic fibrosis and gastrointestinal issues. In the announcement, Forest Labs said it expects the acquisition to add 78 cents per share to earnings in 2015 along with nearly $700 million in revenue. On the news, shares of Forest Labs surged more than 15%.
Any ideas and opinions presented in all Market News Video clips are for informational and educational purposes
only, and do not reflect the opinions of BNK Invest, Inc. or any of its affiliates, subsidiaries or partners.
In no way should any content contained herein be interpreted to represent trading or investment advice.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. Read Full Disclaimer.
X
Wait! Don't leave yet.
Want to receive our latest research absolutely free?
⤹
Click the button below for your complimentary copy of Your Early Retirement Portfolio: Dividends Up to 8.7%—Every Month—Forever.
You'll discover the details on 4 stocks and funds that pay you massive dividends as high as 8.7%.